Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00498797
What this trial is testing

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Who this might be right for
Prostate CancerMetastaticHormone Refractory
Sanofi 86
Testing effectiveness (Phase 2)Study completedNCT00039104
What this trial is testing

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00430235
What this trial is testing

BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer

Who this might be right for
Adenocarcinoma of the Prostate
British Columbia Cancer Agency 39
Testing effectiveness (Phase 2)Study completedNCT00040586
What this trial is testing

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Who this might be right for
Prostatic Neoplasms
BZL Biologics
Testing effectiveness (Phase 2)Study completedNCT00476645
What this trial is testing

Fulvestrant in Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic NeoplasmsProstate Cancer
Stanford University 10
Testing effectiveness (Phase 2)Study completedNCT00027781
What this trial is testing

MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC 37
Testing effectiveness (Phase 2)Study completedNCT00050596
What this trial is testing

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Ended earlyNCT00521274
What this trial is testing

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
The Methodist Hospital Research Institute 11
Testing effectiveness (Phase 2)UnknownNCT00005960
What this trial is testing

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
PainProstate Cancer
Amgen
Testing effectiveness (Phase 2)Study completedNCT00323882
What this trial is testing

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate CancerNeoplasm Metastasis
Bristol-Myers Squibb 75
Not applicableStudy completedNCT00636090
What this trial is testing

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Duke University 35
Testing effectiveness (Phase 2)Study completedNCT00257478
What this trial is testing

The Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Who this might be right for
Prostate CancerCancer of ProstateProstatic Cancer+1 more
Astellas Pharma Inc
Testing effectiveness (Phase 2)Ended earlyNCT00176527
What this trial is testing

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
University of Medicine and Dentistry of New Jersey 40
Testing effectiveness (Phase 2)Study completedNCT00251225
What this trial is testing

Imatinib and Docetaxel in Prostate Cancer

Who this might be right for
Prostate Cancer
Leonard Appleman 49
Testing effectiveness (Phase 2)Study completedNCT00411528
What this trial is testing

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Novartis Pharmaceuticals 185
Testing effectiveness (Phase 2)Study completedNCT00831467
What this trial is testing

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

Who this might be right for
Hormonal Refractory Prostate Cancer
CureVac 48
Early research (Phase 1)Study completedNCT00663832
What this trial is testing

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 44
Testing effectiveness (Phase 2)Ended earlyNCT00126230
What this trial is testing

Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris 55
Testing effectiveness (Phase 2)Study completedNCT00016393
What this trial is testing

BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)WithdrawnNCT00003622
What this trial is testing

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Who this might be right for
Prostate Cancer
James Ahlgren
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation